Editorial

How to Design Clinical Trials in the Era of Targeted Therapies

Antibody–drug conjugates or ADCs are a burgeoning class of targeted therapies designed to deliver dual therapies in a single,...

A New Dawn

It's a new dawn. It's a new day. These powerful words in one of my favorite songs ("Feeling Good") by...

ADCT-301 – A Novel Antibody-drug Conjugate Against Lymphomas – Moves Into Phase I Clinical...

ADC Therapeutics Sarl (Epalinges, Switzerland), a company involved in the development of antibody-drug conjugates against solid and hematological cancers, has filed an...

Positive Toxicology & Production Data on ADCs Generated with SMARTag™ Technology

Over the last decades antibody drug conjugates have received much attention.  This is, in part, due to their huge...

Immuno-Oncology SEA-CD40 Moves Into Phase I Clinical Trial for Advanced Solid Tumors

Earlier today, Seattle Genetics Inc, announced the initiation of a new Phase I clinical trial of SEA-CD40, which utilizes...

The Business of Bispecific Antibodies: Generating Focused Development Libraries

Bispecific antibodies (BsAb), widely used in the development of anticancer immunotherapy, are proteins capable of simultaneously binding two different...

Sanofi and Catalent Develop Next-Gen ADCs with SMARTag Technology

Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer...

Advancing Immunotherapy and the Future of Care: Nantworks Collaborates with Sorrento Therapeutics and Phoenix...

NantWorks, LLC, a California-based medical technology company and Sorrento Therapeutics, Inc, an oncology company developing new, targeted, treatments for cancer,...

Characterization of Antibody-drug Conjugates by Mass Spectrometry

Therapeutic antibody-drug conjugates or ADCs combine a target specific monoclonal antibody or mAb with the cell-killing activity of a...

Design and Synthesis of Novel Auristatin Analogs with N-terminal Modifications

Auristatins, the structurally related synthetic analogs of the antitumor agent Dolastatin 10, a pentapeptide originally isolated from the sea...